<?xml version="1.0" encoding="UTF-8"?>
<p>In ‘
 <bold>Switching to another antihypertensive effective drug when using ACEIs/ARBs to treat arterial hypertension during COVID-19</bold>’, Michele Mario Ciulla from the University of Milan in Italy comment on the 
 <italic>Viewpoint</italic> article also published in this issue entitled ‘
 <bold>SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?</bold>’ by Kuster 
 <italic>et al</italic>. 
 <xref rid="ehaa435-B9" ref-type="bibr">
  <sup>9</sup>
 </xref>
 <sup>,</sup>
 <xref rid="ehaa435-B26" ref-type="bibr">
  <sup>26</sup>
 </xref> Kuster 
 <italic>et al</italic>. respond in a separate contribution.
 <xref rid="ehaa435-B27" ref-type="bibr">
  <sup>27</sup>
 </xref>
</p>
